Cosmos Health Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Grigorios Siokas
- Full Time Employees
- 149
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 141 West Jackson Boulevard Chicago IL United States of America 60604
- IPO Date
- Jul 23, 2010
- CIK
- 0001474167
- Website
- cosmosholdingsinc.com
- Similar Companies
- Business
- Cosmos Health Inc. (NASDAQ: COSM) operates as a diversified, vertically integrated global pharmaceutical holding company that develops, manufactures, and distributes proprietary nutraceuticals, branded generics, over-the-counter medications, medical devices, cosmetics, food supplements, and healthcare products; its core brands include Sky Premium Life, Mediterranation, bio-bebe, C-Sept, and C-Scrub, with additional offerings in vitamins, minerals, herbal extracts, and specialized root extracts produced under European Good Manufacturing Practices through subsidiary Cana Laboratories S.A. The company serves retail pharmacies, wholesale distributors, hospitals, and healthcare providers with a broad portfolio encompassing prescription drugs, OTC products, and nutraceuticals targeted at wellness, prevention, and therapeutic needs in areas such as obesity, diabetes, and cancer. Founded in 2009 and headquartered in Chicago, Illinois, Cosmos Health maintains operations across Europe, the UK, Asia, and North America, with key facilities in Thessaloniki and Athens, Greece, and Harlow, UK; it also provides healthcare distribution through EU and UK subsidiaries and has expanded into telehealth via its acquisition of ZipDoctor, Inc. in Texas, USA. In recent developments, Cosmos Health launched a long-term strategic partnership with Prime Ledger LLC on December 3, 2025, to manage its $300 million treasury facility, implement blockchain-based controls and reporting, and tokenize high-value intellectual property assets. The company commenced U.S. operations in September 2025 with its Sky Premium Life brand, leveraging local manufacturing to enter the $164 billion nutraceuticals market, while advancing R&D initiatives including AI-enhanced drug repurposing, nanotechnology for dietary supplements, and proprietary complex generics. CEO Greg Siokas increased his ownership by acquiring 301,101 shares in late 2025, signaling confidence amid record Q3 2025 results, and the firm diversified investments with Ethereum purchases totaling $2 million.
Cosmos Health enters animal health market with C-Scrub brand
Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months
Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed
Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months
Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products
Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio
Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health
Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30%
Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 2026 Across All Core Segments
Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units
Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months
Cosmos Health Continues Expansion in the United States with Q2 Launch of Liv18 - a Clinically Proven, Patented Supplement for Liver Fat Reduction
Summit Therapeutics (NASDAQ:SMMT) and Cosmos Health (NASDAQ:COSM) Financial Contrast
Contrasting Profound Medical (NASDAQ:PROF) and Cosmos Health (NASDAQ:COSM)